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Abstract: Chikungunya fever is an arthropod-borne infection caused by Chikungunya virus
(CHIKV). Even though clinical features of Chikungunya fever in the Mexican population have
been described before, there is no detailed information. The aim of this study was to perform a full
description of the clinical features in confirmed Chikungunya-infected patients and describe the
molecular epidemiology of CHIKV. We evaluated febrile patients who sought medical assistance in
Tapachula, Chiapas, Mexico, from June through July 2015. Infection was confirmed with molecular
and serological methods. Viruses were isolated and the E1 gene was sequenced. Phylogeny
reconstruction was inferred using maximum-likelihood and maximum clade credibility approaches.
We studied 52 patients with confirmed CHIKV infection. They were more likely to have wrist,
metacarpophalangeal, and knee arthralgia. Two combinations of clinical features were obtained to
differentiate between Chikungunya fever and acute undifferentiated febrile illness. We obtained
10 CHIKV E1 sequences that grouped with the Asian lineage. Seven strains diverged from the
formerly reported. Patients infected with the divergent CHIKV strains showed a broader spectrum of
clinical manifestations. We defined the complete clinical features of Chikungunya fever in patients
from Southeastern Mexico. Our results demonstrate co-circulation of different CHIKV strains in the
state of Chiapas.
Keywords: alphavirus; Chikungunya fever; phylogeny; Mexico
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1. Introduction
Chikungunya virus (CHIKV) is transmitted by the bite of the Aedes aegypti and Aedes albopictus
mosquitoes. It produces an acute illness with high fever, joint pain, head, and muscular pain. Even
though it rarely causes death, joint pain can last months or years, develop chronicity and cause
disability [1,2]. There are neither specific antiviral drugs nor available vaccines to prevent the infection.
Since its discovery in 1952, CHIKV has caused massive outbreaks in Africa and Southeast
Asia [3,4]. One of the most studied CHIKV outbreaks was the one that occurred in La Réunion Island
in 2005, where clinical manifestations were recorded in detail and chronic pain was reported [5–8].
From December 2013 through the epidemiological week 45 in 2017, CHIKV has caused more than
331,000 confirmed infections in the American continent [9]. In Mexico, until 4 November 2017, there
have been more than 12,500 confirmed cases [10].
Chikungunya virus is a member of the Alphavirus genus in the Togaviridae family and its genome
is approximately 12 kb in length [11]. There are four identified CHIKV lineages: West African,
East/Central/South African (ECSA), Asian, and Indian Ocean lineage. The later was derived from the
ECSA lineage and arose from La Réunion outbreak. This new lineage had the substitution A226V at
the E1 protein, which together with other mutations, allowed the infection of A. albopictus mosquitoes
in a greater extent [12,13]. The Asian lineage is the responsible for the outbreak in the American
continent [1,14–16]. Nevertheless, the ECSA lineage also circulates in Brazil [17–19].
Chikungunya fever (CHIKF) is characterized by an abrupt febrile illness, polyarthralgia and
maculopapular rash, after 2 to 4 days of incubation period. Arthralgia can be incapacitating and last
for weeks. In contrast to other illnesses, the majority of the infections (85%) are symptomatic [6,20].
Arthralgia is symmetrical and bilateral, localized at the upper and lower limbs [21]. According to
studies conducted during La Réunion outbreak the affected joints were: ankles, knees, hands, wrists,
feet, shoulder and elbows. Fifty-four of the patients reported rash, particularly on trunk and arms.
Arthritis we reported by 45% of the patients, being the ankle was the most affected joint. Myalgia
and headache affected more than half of the patients [5,8,22,23]. The case definition of acute clinical
cases includes fever and joint pain with acute onset and/or epidemiological and laboratory criteria.
Epidemiological criteria consist of residing or traveling to an endemic CHIKV region. A chronic case
consists of previous clinical diagnosis of CHIKF 12 weeks after symptom onset and presentation with
at least one joint manifestation that is continuous or recurrent [24,25].
Even though clinical features of CHIKF in Mexican population have been described before [26–28],
arthralgia, arthritis, and rash are mentioned as a whole without describing the specific affected joints or
areas. A detailed analysis of the spectrum of clinical signs can help to identify specific manifestations
that could aid clinicians to distinguish CHIKF from other similar viral illnesses. Although there are a
great number of available CHIKV sequences, Mexican sequences are scarce. In addition, the existence
of different CHIKV circulating in Chiapas and if there are associated clinical features is unknown.
The aim of this study was to make a full description of the clinical features in Chikungunya-infected
patients, and the molecular epidemiology of CHIKV.
2. Materials and Methods
2.1. Ethical Aspects
The study was conducted in accordance with the Declaration of Helsinki, and the protocol
was reviewed and approved by the Ethics Committee from Facultad de Medicina y Hospital
Universitario—Universidad Autónoma de Nuevo León with the following registration number:
IF12-003 (approval date: 20 August 2012). All study participants provided informed written consent
prior to study enrollment. All patient samples and data were assigned institution-specific identification
numbers to ensure patient anonymity.
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2.2. Study Population, Recruitment and Sample Collection
We studied patients who sought medical assistance at the secondary-level Hospital Clinic
“Dr. Roberto Nettel Flores” in Tapachula, Chiapas, Mexico, from June through July 2015. This health
clinic receives only State workers and their immediate relatives, not open to the general population.
Patients were eligible for enrollment if they were ≥18 years old and febrile (temperature ≥37.5 ◦C) or
had history of fever within last five days, accompanied by one or more of the following symptoms:
polyarthralgia, headache and/or rash. Individuals with another identifiable infection were excluded.
Clinical information and physical examination were recorded. The visual analogue scale (VAS) was
used to evaluate pain intensity and patients were inquired if they needed help to fulfill simple tasks.
A single whole blood sample was collected at the enrollment day and sera samples were stored at
−70 ◦C until further use. Fourteen months after the onset of symptoms, patients were contacted by
telephone and inquired for CHIKF symptomatology. Patient home addresses were used to identify
longitude and latitude coordinates. ArcGIS v10.2.2 (ESRI, Redlands, CA, USA) was used to overlay
the resulting points and carry out the geospatial analysis. According to the female mosquito flight
range, a 400 m buffer distance was applied to each positive dwelling [29].
2.3. Viral RNA Detection
RNA extraction was performed using QIAamp UltraSens Virus Kit (QIAGEN, Valencia, CA,
USA). Screening for CHIKV was carried out using the nsp4 one-step, probe-based, real-time reverse
transcription PCR assay (rRT-PCR) described by Lanciotti [30]. Chikungunya positive and negative
samples were screened and serotyped for Dengue viruses (DENV) using the protocol described by
Seah [31]. Chikungunya negative samples were screened for Zika virus (ZIKV) using the rRT-PCR
assay with the primer/probe set with higher sensitivity described by Lanciotti [32]. All rRT-PCR
assays were done using the SuperScript III Platinum One-Step qRT-PCR kit (Invitrogen, Carlsbad, CA)
in a 7500 Fast Real-Time PCR System (Applied Biosystems, Carlsbad, CA, USA).
2.4. Specific IgM Enzyme-Linked Immunosorbent Assay (ELISA)
InBios CHIKjj Detect IgM ELISA (Seattle, WA, USA) was used to screen sera for the presence
of CHIKV-specific IgM antibodies, following manufacturer’s instructions [33]. Samples were
designated as positive for CHIKV-specific IgM if they returned a value of ≥1 and as negative at <1.
We used an in-house, luminometric, E protein-based ELISA to detect dengue-specific IgM antibodies
(R. Vidaltamayo, unpublished data [34]). The ELISA plates were read at the GloMax Discover System
(Promega, Madison, WI, USA). All samples were run in triplicate.
2.5. E1 Gene Amplification and Sequencing
The PrimeScript RT-PCR Kit (TaKaRa, Shiga, Japan) was used to generate one PCR amplicon
(1623 nt) from the E1 region. The amplicon was then purified using the QIAquick PCR Purification Kit
(Qiagen). Sequencing was performed on a 3500 Genetic Analyzer (Applied Biosystems) using BigDye
Terminator v3.1 cycle sequencing kit (Applied Biosystems). Sequences were assembled based on the
reference Chikungunya virus sequence from NCBI: NC_004162.2. The sequences were deposited in
GenBank under the following accession numbers: MG525024—MG525033.
2.6. Phylogenetic Analysis
The newly obtained E1 gene nucleotide sequences and sequences from GenBank were aligned
using the MUSCLE algorithm. We included sequences of the four previously described CHIKV
lineages (West Africa, ECSA, IOL and Asian). The final data set comprised of 73 E1 coding sequences
(1317 nt in length) from 32 countries isolated during 1953–2015 (Table S1). The evolutionary history
was inferred using the maximum-likelihood method in MEGA v6.06 (Arizona State University,
Tempe, AZ, USA) [35] and the maximum clade credibility (MCC) in BEAST v1.8.2 (University of
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Edinburgh, Edinburgh, United Kingdom) [36]. For the phylogenic reconstruction, we used the
Hasegawa-Kishino-Yano substitution model [37] with a discrete Gamma distribution (4 categories).
For the MCC approach we used a strict clock model with a coalescent constant size tree. In the
maximum-likelihood approach we used a bootstrap of 1000 replicates and in the maximum clade
credibility approach, 10 million generations with 10% removed as burn-in. The trace files generated
were visualized in the software package Tracer v1.6 (University of Edinburgh) [38]. The obtained
effective sample size was greater than 200. The best-supported tree was obtained with the TreeAnotator
program excluding the first 10% of trees as burn-in.
2.7. Statistical Analysis
The frequencies of patient demographic and clinical characteristics were determined. The outcome
for analysis was having a confirmed infection with CHIKV, defined as a positive result on CHIKV
rRT-PCR or positive CHIKV-specific IgM antibodies. Bivariable associations with a confirmed CHIKV
infection were determined using the Fisher’s exact test. Continuous variables with normal distribution
were analyzed with Student’s t-test and variables with non-normal distribution with Mann-Whitney U
test. All variables with a p-value less than or equal to 0.25 were considered in the multivariable model,
which was determined using binary logistic regression using a backward stepwise selection procedure
(entry: 5%, exit: 10%). Odds ratios were adjusted for age and gender. Data was entered and analyzed
using IBM SPSS Statistics v20 (IBM Corporation, Armonk, NY, USA) for analysis. All p-values <0.05
were considered significant. Positive predictive values (PPVs), negative predictive values (NPVs),
sensitivity, specificity and likelihood ratios of different combinations of clinical features were used to
distinguish CHIKF from other acute undifferentiated fever illness (AUFI).
3. Results
There were 61 patients who met the inclusion criteria and agreed to participate in the study. Sixty
seven percent were female and the median age was 43 years old, ranging from 18 to 69 years. Eleven
percent reported previous dengue fever (confirmed by serology) and 39% reported that others in their
household had been febrile in a two-week interval prior to the interview.
From the 61 enrolled patients, 52 (85%) were positive for CHIKV infection (CHIKV+) either by
rRT-PCR or IgM ELISA. Among the positive cases, 33 patients (64%) had CHIKV viral RNA detected in
serum by rRT-PCR and 19 patients (36%) had IgM anti-CHIKV antibodies. No samples were positive
for the two diagnostic tests. Samples were positive by rRT-PCR from day one to four after onset of
symptoms. IgM anti-CHIKV antibodies were detected from day two to day nine. The remaining nine
patients (CHIKV negative) were evaluated for DENV and ZIKV by RT-PCR and rRT-PCR, respectively.
We found neither DENV nor ZIKV viral RNA nor IgM anti-DENV antibodies in the serum samples.
Therefore, these patients were classified as AUFI. Because DENV is endemic in the Chiapas state,
DENV co-infection was investigated. Chikungunya rRT-PCR positive samples were evaluated for
DENV by RT-PCR. However, we found no CHIKV and DENV co-infection in the studied patients.
As for ZIKV, at the time of patient enrollment, there was no ZIKV circulation at the Chiapas state.
Nevertheless, ZIKV was searched intentionally in the negative samples.
The CHIKV+ patients were distributed across eight Chiapas’ municipalities. Thirty-nine patients
(75%) lived in the city of Tapachula. We were able to obtain 39 home addresses of the confirmed
CHIKV cases, 30 from Tapachula and nine from the rest of the cities. Patients from Tapachula had
their dwellings distributed across the city. Based on well-documented average flight range distance
of less than 400 m for A. aegypti females, a 200 m range was applied to the patient’s dwelling [39,40].
This resulted with seven clusters of cases across the city. Five clusters involved two dwellings and two
clusters involved three to four dwellings (Figure 1). The mean distance between each dwelling in the
clusters was 240 m.
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Figure 1. Distribution of confirmed Chikungunya fever cases in Tapachula, Chiapas. Chikungunya 
fever cases are marked. Concentric distance in meters is shown. The date of the patient’s enrolment 
is indicated. Patients enrolled in June and July are marked with a filled and hollow shape, 
respectively. The upper left square indicates the location of Tapachula municipality and Chiapas state. 
We used the World Light Gray Base by Esri (Esri Inc., Redlands, CA, USA) [41]. 
3.1. Comparison of Chikungunya—Positive Patients versus Acute Undifferentiated Febrile Illness Patients 
When we compared CHIKV+ patients with AUFI patients, there was no difference in the time of 
onset of symptoms (both median 3 d). Patients with confirmed CHIKF were older than AUFI patients 
(mean years 42.8 and 36.4, respectively), but not significant. Chikungunya-infected patients were 
predominantly females (73%) compared to AUFI patients that were predominantly males (67%), 
being significant (p = 0.04). 
There were no significant differences in clinical presentations between those with CHIKV 
confirmed infection and those without (Table 1). However, CHIKV+ patients reported arthritis and 
Figure 1. Distribution of confirmed Chikungunya fever cases in Tapachula, Chiapas. Chikungunya
fever cases are marked. Concentric distance in meters is shown. The date of the patient’s enrolment is
indicated. Patients enrolled in June and July are marked with a filled and hollow shape, respectively.
The upper left square indicates the location of Tapachula municipality and Chiapas state. We used the
World Light Gray Base by Esri (Esri Inc., Redlands, CA, USA) [41].
3.1. Comparison of Chikungunya—Positive Patients versus Acute Undifferentiated Febrile Illness Patients
When we compared CHIKV+ patients with AUFI patients, there was no difference in the time of
onset of symptoms (both median 3 d). Patients with confirmed CHIKF were older than AUFI patients
(mean years 42.8 and 36.4, respectively), but not significant. Chikungunya-infected patients were
predominantly females (73%) compared to AUFI patients that were predominantly males (67%), being
significant (p = 0.04).
There were no significant differences in clinical presentations between those with CHIKV
confirmed infection and those without (Table 1). However, CHIKV+ patients reported arthritis
and adenopathy in a greater proportion. Arthritis distribution is shown in Table 2. One patient,
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chikungunya-infected, had five joints affected by arthritis. Retroauricular adenopathy was the most
commonly reported presentation.
Table 1. Clinical features of the studied patients in Tapachula, Chiapas, June through July 2015 a.
Symptom CHIKV+n = 52
AUFI
n = 9 p-Value
b rRT-PCR
n = 33
IgM
n = 19 p-Value
c
Arthralgia 51 (98) 8 (89) 0.275 33 (100) 18 (95) 0.365
Myalgia 51 (98) 9 (100) 1.000 33 (100) 18 (95) 0.365
Headache 47 (90) 8 (89) 1.000 32 (97) 15 (79) 0.054
Retroocular pain 16 (31) 4 (44) 0.458 12 (36) 4 (21) 0.353
Conjunctival hyperemia 21 (40) 3 (33) 1.000 13 (39) 8 (42) 1.000
Shivers 44 (85) 6 (67) 0.343 29 (88) 15 (79) 0.443
Asthenia 39 (75) 4 (44) 0.108 25 (76) 14 (74) 1.000
Rash 32 (62) 5 (56) 0.729 18 (55) 14 (74) 0.240
Pruritus 35 (67) 5 (56) 0.706 22 (67) 13 (68) 1.000
Arthritis * 34 (65) 1 (11) 0.003 * 21 (64) 13 (68) 0.771
Adenopathy 25 (48) 1 (11) 0.065 13 (39) 12 (63) 0.150
Vertigo 17 (33) 3 (33) 1.000 9 (27) 8 (42) 0.360
Gastrointestinal symptoms 50 (96) 8 (89) 0.386 32 (97) 18 (95) 1.000
Abdominal pain 20 (39) 3 (33) 1.000 13 (39) 7 (37) 1.000
Anorexia 40 (77) 6 (67) 0.676 27 (82) 13 (68) 0.317
Dysgeusia 39 (75) 4 (44) 0.108 26 (79) 13 (68) 0.510
Diarrhea 15 (29) 5 (56) 0.139 7 (21) 8 (42) 0.126
Nausea 34 (65) 5 (56) 0.710 24 (73) 10 (53) 0.226
Vomit 5 (10) 2 (22) 0.273 2 (6) 3 (16) 0.342
Hemorrhagic signs 12 (23) 4 (44) 0.224 7 (21) 5 (26) 0.739
Epistaxis 3 (6) 0 1.000 1 (3) 2 (11) 0.546
Gingivorrhagia 5 (10) 2 (22) 0.273 4 (12) 1 (5) 0.641
Petechiae 5 (10) 2 (22) 0.273 3 (9) 2 (11) 1.000
a Values are no. (%) patients. CHIKV, chikungunya virus; AUFI, acute undifferentiated fever illness; rRT-PCR,
real-time reverse transcription PCR; IgM: immunoglobulin M. b CHIKV+ vs. AUFI. c rRT-PCR vs. IgM. * p < 0.01.
Fisher exact test.
Table 2. Arthritis and Rash distribution of the studied patients in Tapachula, Chiapas, June through
July 2015 a.
Symptoms CHIKV+n = 52
AUFI
n = 9 p-Value
b rRT-PCR
n = 33
IgM
n = 19 p-Value
c
Arthritis Wrist 1 (2) 0 1.000 1 (3) 0 1.000
MCP 2 (4) 0 1.000 2 (6) 0 0.527
PIP 4 (8) 0 1.000 4 (12) 0 0.284
DIP 2 (3) 0 1.000 2 (6) 0 0.527
Knee 5 (10) 0 1.000 4 (12) 1 (5) 1.000
Ankle 13 (25) 1 (11) 0.430 9 (27) 4 (21) 1.000
MTP 1 (2) 0 1.000 1 (3) 0 1.000
Rash Face 1 (2) 0 1.000 1 (3) 0 1.000
Neck 2 (4) 1 (11) 0.386 1 (3) 1 (5) 1.000
Chest 7 (14) 3 (33) 0.157 3 (9) 4 (21) 0.400
Abdomen 10 (19) 1 (11) 1.000 4 (12) 6 (32) 0.142
Forearm 18 (35) 4 (44) 0.710 9 (27) 9 (47) 0.226
Arm 16 (31) 3 (33) 1.000 8 (24) 8 (42) 0.220
Thigh 12 (23) 1 (11) 0.669 6 (18) 6 (32) 0.317
Leg 9 (17) 0 0.332 3 (9) 6 (32) 0.059
Feet 1 (2) 0 1.000 0 1 (5) 0.365
Back 9 (17) 0 0.361 4 (12) 5 (26) 0.260
Buttocks 4 (8) 0 1.000 1 (3) 3 (16) 0.132
a Values are no. (%) patients. CHIKV, chikungunya virus; MCP, metacarpophalangeal joint; PIP, proximal
interphalangeal joint; DIP, distal interphalangeal joint; MTP, metatarsophalangeal joint. b CHIKV+ vs. AUFI.
c rRT-PCR vs. IgM.
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Patients manifested symmetrical arthralgia. Chikungunya positive patients reported a higher
number of arthralgia-involved joints (median 38) compared to AUFI patients (median 13) being
significant (p < 0.01). In CHIKV+ patients, arthralgia was present in a significantly greater proportion
in specific joints (Figure 2a). Rash was located mainly in upper limbs, leaving hands unaffected. Lower
limbs were also affected, especially in CHIKV+ patients (Table 2).
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Figure 2. Arthralgia and arthritis distribution in the studied patients from Tapachula, Chiapas, June
through July 2015. (a) Arthralgia distribution in the CHIKV+ and AUFI patients. The reported
arthralgia was symmetrical. For illustrative purposes only, unilateral joints are indicated. Values are no.
(%) patients; (b) Arthralgia and arthritis distribution on the first interview and after 14 months in the
four studied patients. Values are % of patients in the first and second interview. CHIKV+, positive for
chikungunya virus infection; AUFI, acute undifferentiated febrile illness; MCP, metacarpophalangeal
joint; PIP, proximal interphalangeal joint; DIP, distal interphalangeal joint; MTP, metatarsophalangeal
joint. * p < 0.05, ** p < 0.01, Fisher exact test.
Forty-nine percent of the patients reported to need some help to fulfill their daily activities
(n = 45), and all of them were CHIKV+ patients. Patients needed help mostly for lifting from a sitting
position and walking (74 and 68% respectively). Chikungunya-infected patients had higher VAS score
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(median 8) compared to the AUFI patients (median 7) (p < 0.01). The chikungunya-infected female
patients reported more pain (median 9) than males (median 7) (p < 0.01). Pain was not associated with
the increasing age.
After the multivariate analysis, patients who had confirmed CHIKV infection were significantly
more likely to have wrist, metacarpophalangeal and knee arthralgia. Similarly, patients who had
confirmed CHIKV infection were significantly more likely to have a high VAS score and a high number
of arthralgia involved joints (Table 3).
Table 3. Multivariate analysis associated with Chikungunya fever in southeastern Mexican population a.
Parameter Adjusted Odds Ratio b (95% Confidence Interval) p-Value
Arthritis
Yes 6.61 1.24–35.19 0.027
Wrist arthralgia
Yes 22.1 2.58–188.74 0.005
MCP arthralgia
Yes 6.2 1.25–30.67 0.025
Knee arthralgia
Yes 5.89 1.17–29.49 0.031
VAS score 1.61 1.066–2.440 0.024
Number of involved joints 1.05 1.004–1.100 0.033
a MCP, metacarpophalangeal; VAS, visual analog scale. b Adjusted for age and gender.
We could interview four CHIKV+ patients, out of 52, after 14 months of the onset of symptoms.
The mean age was 51 years old and 75% were female. None of them considered themselves cured
after the 14 months. Three patients reported a pain-free period. When interviewed, all the patients
still had pain. The male patient reported having higher pain at the second interview (VAS score 4 vs.
7). Half of the patients reported that pain negatively affected their quality of life, and three-fourths
reported mood change. Half of the patients still required some help to fulfill their daily activities.
The arthralgia and arthritis distribution presented by the four studied patients at enrollment day and
after 14 months is shown in Figure 2b. Hand arthralgia resolved in almost all patients, in contrast, knee
arthralgia continued in all of them. Half of the patients developed arthralgia in previously pain-free
joints. Hand arthritis resolved in the affected patients. Nevertheless, two patients developed knee and
wrist arthralgia (Figure 2b).
3.2. Comparison of Patients Diagnosed by rRT-PCR versus IgM ELISA
We compared patients that were CHIKV+ by rRT-PCR and IgM ELISA. Overall, there were
almost no differences. The proportion of female patients confirmed by rRT-PCR and ELISA was
61% and 95% respectively. Ninety-three percent of the total males were confirmed as CHIKV+ by
rRT-PCR. Patients confirmed by rRT-PCR and ELISA showed the same clinical manifestations (Table 1).
The exception was adenopathy, which was present at a greater proportion in ELISA-confirmed patients
but not significant. Patients from both groups showed similar arthralgia distribution. The elbow was
affected on a greater proportion in patients confirmed by rRT-PCR (p = 0.04). Rash affected a greater
proportion of patients in the IgM group (Table 2). The number of rash affected areas increased as the
time post-onset of symptoms increased. Sixty percent of the patients in the rRT-PCR group required
help to fulfill their daily activities, compared to the IgM group where only 28% required help (p > 0.05).
Patients from rRT-PCR and IgM group had similar VAS scores, median of 9 and 8 respectively. Females
from the RT-qPCR group reported greater pain than males (p = 0.001).
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3.3. Distinguishing Chikungunya Fever from Acute Undifferentiated Febrile Illness Using Clinical Features
We found two combinations of clinical features that can be used to differentiate CHIKF from
AUFI. One option considers arthralgia in wrist, metacarpophalangeal joints, and knee. The other one
considers arthralgia in the same areas plus adenopathy, arthritis and more than 30 arthralgia-involved
joints. Both combinations have sensitivity and positive predictive value above 90%. The combination
using arthralgia alone has better specificity (83%) than the broader combination (75%). Yet, the broader
combination has a higher negative predictive value (Table 4).
Table 4. Clinical features used to distinguish patients with Chikungunya fever from patients with
AUFI a.
Parameter PPV(%)
NPV
(%)
Sens
(%)
Spec
(%)
Likelihood
Ratio (+)
Likelihood
Ratio (−)
Wrist arthralgia 96.1 44.4 90 66.6 2.72 0.13
Wrist, MCP and knee arthralgia 98 55 92.7 83.3 5.56 0.08
Wrist, MCP and knee arthralgia, plus
arthritis (or adenopathy) 98 44.4 91 80 4.55 0.11
MCP and knee arthralgia plus
≥8 VAS score 96 62.5 94.2 71.4 3.29 0.08
Wrist, MCP and knee arthralgia, ≥30
joints involved, arthritis and adenopathy 96.1 66.6 94.3 75 3.77 0.07
a AUFI, acute undifferentiated febrile illness; PPV, positive predictive value; NPV, negative predictive value; Sens,
sensitivity; Spec, specificity; MCP, metacarpophalangeal; VAS, visual analog scale.
3.4. Phylogenetic Analysis
We obtained ten complete E1 gene sequences from patients’ isolates. Nucleotide identity among
the sequences was 99.6–100% and 99.8–100% at the amino acid level. When compared to the British
Virgin Island’s isolate (KJ451624.1), we found nine synonymous substitutions and one non-synonymous
substitution. The non-synonymous substitution occurred in the E1 protein at the nucleotide position
3452 (C→ T) changing the amino acid residue 342 (A→ V).
The maximum-likelihood and Bayesian approaches showed that the newly obtained CHIKV
sequences clustered with the rest of the Caribbean isolates in the Asian lineage (Figure 3a). Former
reported CHIKV sequences from Chiapas state in 2014 [42], clustered with the sequences reported
from other countries in the Caribbean, Central and South America, from 2013 to 2016. Three of
the newly obtained sequences clustered with the formerly reported sequences from Chiapas. These
sequences were from Cacahoatan, Mazatan and Tapachula. Four of the sequences formed their own
monophyletic group with a bootstrap support and posterior probability greater than 60 (Figure S1).
One monophyletic group was composed of the two samples from Tuxtla Chico. The two remaining
groups were made of a sample from Tapachula and a sample reported from Yucatán state. Two
samples from Tapachula and one from Huixtla diverged from the former sequenced viruses but with
low bootstrap and posterior probability values (Figure 3b). Sequences that were identical to the former
reported Chiapas’ strains were denominated ancestral. Not identical samples were denominated
divergent. There were several Chikungunya viruses circulating in Chiapas state during June and July
2015 (Figure 4). Different viruses were circulating in the city of Tapachula. It is interesting that patients
from the same infection cluster were infected with different viruses. Such is the case of strains TA-689
and TA-755 (Figures 1 and 3b). Even though patients had their dwellings separated 110 m from each
other, the strains had three transitions and one transversion. Strain TA-755 grouped with a strain
from Yucatan with a high bootstrap and posterior probability value, confirming the difference from
strain TA-689.
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Figure 3. Maximum Likelihood phylogeny based on the E1 gene of 73 CHIKV sequences. The four
CHIKV lineages are shown. Bold numbers at nodes correspond to the bootstrap value. Only bootstrap
values above 50 are shown. The tree is drawn to scale, with branch lengths measured in the number of
substitutions per site. (a) Strains isolated from Tapachula, Chiapas, 2015 belong to the Asian lineage. (b)
Magnification of the discontinue box in (a), that shows the relationship of the newly and previously [42]
sequenced strains. Sequences that were identical to the previously reported were considered ancestral,
the others were considered divergent. The previously sequenced strains are indicated with a circle.
The newly sequenced strains are indicated with a triangle. The triangles of the divergent sequences
are darker.
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Figure 4. Chikungunya virus strains distribution across Chiapas, Mexico, 2014–2015. The different
municipalities were CHIKV was isolated and sequenced are labeled. The upper right square indicates
the location of Tapachula municipality and Chiapas state. The middle right square is a magnification of
the sequences from Tapachula and Tuxtla Chico. The previously sequenced strains [42] are indicated
with a circle. The newly sequenced strains are indicated with a triangle. The triangles of the divergent
sequences are darker. We used the World Light Gray base by Esri (Esri Inc.) [41].
3.5. Chikungunya Virus Strain—Specific Clinical Manifestations
We compared the clinical manifestations of the patients with sequenced CHIKV strains.
The patients were grouped according to their infecting strain, ancestral or divergent. Three patients
formed the ancestral group and seven patients the divergent group. The ten studied patients had a
mean age of 44 years old and 60% were female. There was no difference regarding age and gender
between the two groups.
Patients from both groups showed a similar symptomatology. Nevertheless, patients infected with
the divergent strains reported arthritis and asthenia at a significantly greater proportion. Adenopathy
and vertigo were also present in greater proportion, but not significant. Even though the ten patients
reported gastrointestinal symptoms, only patients in the divergent group reported abdominal pain and
diarrhea (Table 5). There was no difference in the arthralgia distribution. Patients from the divergent
group reported arthritis mostly in the proximal interphalangeal joints and the ankle (both 43%).
Patients from the ancestral group only reported rash at the face and neck in one patient. In contrast,
two patients from the divergent group reported rash at the arms and forearms.
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Table 5. Clinical features of patients infected with the isolated CHIKV strains a.
Symptoms Ancestral n = 3 Divergent n = 7 p-Value
Arthralgia 3 (100) 7 (100) b
Myalgia 3 (100) 7 (100) b
Headache 3 (100) 6 (86) 1.000
Retroocular pain 1 (33) 1 (14) 1.000
Conjunctival hyperemia 3 (100) 3 (43) 0.200
Shivers 3 (100) 7 (100) b
Asthenia * 0 6 (86) 0.033 *
Rash 1 (33) 2 (29) 1.000
Pruritus 1 (33) 5 (71) 0.500
Arthritis * 0 6 (86) 0.033 *
Adenopathy 0 4 (57) 0.200
Vertigo 0 2 (27) 1.000
Gastrointestinal symptoms 3 (100) 7 (100) b
Abdominal pain 0 3 (43) 0.475
Anorexia 2 (67) 6 (86) 1.000
Dysgeusia 2 (67) 6 (86) 1.000
Diarrhea 0 2 (29) 1.000
Nausea 2 (67) 5 (71) 1.000
Hemorrhagic signs 0 1 (14) 1.000
Epistaxis 0 1 (14) 1.000
a Values are no. (%) patients. b No statistics were computed because the variable is a constant. CHIKV, Chikungunya
virus. * p < 0.01. Fisher exact test.
Sixty-seven percent of the patients in the divergent group needed help to fulfill their daily
activities, compared to the ancestral group, which no one needed help. The most needed help was to
lift from a sitting position in 67% of the patients. Patients from the divergent group reported a higher
pain (median 9) compared to the ancestral group (median 7) but not significant.
We were able to obtain the sequence of the CHIKV strain that infected three of the four chronic
cases (TC11, TA756 and TA755). The three sequences diverged from the previously reported E1
sequences. Two of them (TC11 and TA755) formed their own monophyletic group.
The patient that was infected with the strain TA725, the virus containing the non-synonymous
mutation A342V, had certain clinical remarks. It was the patient with a higher number of
arthritis-involved joints (metacarpophalangeal, proximal interphalangeal, distal interphalangeal, knee
and ankle). It was one of the patients that reported a VAS score of 10. Also, it was one of the two
patients that needed help to fulfill the four evaluated activities (walk, lift from a sitting position, eat
and bathe).
4. Discussion
We were able to identify 52 patients with confirmed acute CHIKF from eight different
municipalities in the state of Chiapas. In average we saw 4.7 CHIKV-confirmed patients per weekday.
The patients who sought medical attention were middle-aged. This could be explained because
the health clinic receives only State workers and their immediate relatives, not open to the general
population. We found a higher proportion of affected females as reported by Danis-Lozano [28].
This could be due to CHIKV’s home environment transmission as described previously in dengue
seroprevalence reports [43]. Also, a social explanation could be possible. Thompson reported that
women visited their primary care provider to a greater extent than did men for both physical and
mental health concerns [44].
We were not able to identify the etiological agent of the acute undifferentiated febrile illnesses.
Possibly the viruses were cleared in the first days post-onset of symptoms, before patients sought
medical attention. Another possibility is that patients started with mild symptomatology and didn’t
consider themselves sick, arriving too late for viral RNA detection.
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Several patients’ dwellings formed clusters, while others were isolated. The isolated patients can
be explained by the fact that the patients’ neighbors probably were not State workers, therefore sought
medical attention at another place.
When compared to the other studies from Mexico [26–28], arthralgia, headache, and shivers
were present in the same proportion. Arthritis and adenopathy were only reported in patients from
Chiapas. We don’t think that these manifestations are population or virus specific. As the obtained
information from Garay-Moran’s study [27] came from a previously established database, arthritis
could not have been considered even if it was manifested by the patients. Patients from Yucatan
may have manifested arthritis but not taken in consideration. Patients infected with viruses from
the ECSA, IOL and Asian lineages reported arthritis [8,18,22,23,45–52]. Adenopathy was previously
reported in La Réunion [22,23], India [53,54] and Sri Lanka [55,56], where the Indian Ocean Lineage
was circulating. In America, Colombia and Grenada reported patients with adenopathy [15,50]; as well
as travelers from Spain that visited Dominican Republic or Haiti [57]. Just two studies mention the
localization of the affected lymph nodes, with cervical being the most commonly affected [53,57].
In our study, we found retroauricular adenopathy, which can be seen as inflammation of the external
ear. Javelle reported inflammation of the external ear in patients with acute Chikungunya infection at
Malaysia. They suggest looking for inflammation of external ears in all suspected CHIKV cases [58].
Probably CHIKV can be disseminated from the retroauricular lymph nodes to the external ear, or
vice versa.
We observed a greater proportion of patients with hemorrhagic signs than the rest of the Asian
lineage-infected patients. This proportion difference is significant. We are not the only ones who
reported a great proportion in hemorrhagic signs. Staikowsky reported hemorrhagic signs in 28% of
the studied patients from La Réunion [22].
In this study, we report a greater proportion of arthralgia-involved joints. Arthralgia in shoulder,
wrist, metacarpophalangeal joints, hip, knee and ankle were affected in a greater proportion than
patients from La Réunion, India, Sri Lanka, Congo, and Gabon [22,46,55,59,60]. In contrast, cervical
arthralgia was affected at a lower proportion. Arthralgia in elbow, proximal interphalangeal, and
metatarsophalangeal joints was distributed in the same proportion as in other studies [8,23,59].
The patients studied manifested lower proportion of rash affected areas when compared to the
available data from India and La Réunion [22,61]. Only rash on the arm, forearm, and thighs were
affected in a similar proportion.
Patients with confirmed CHIKF complained of higher pain levels than patients with AUFI,
as it was confirmed by the multivariable analysis. Women reported higher pain. This could be
explained because women have greater pain sensitivity compared with men for most experimental
pain modalities [62].
We are the first ones to report chronic post-chikungunya arthralgia in Mexican population after
14 months of onset of symptoms. Patients had an arthralgia-free period nevertheless it relapsed. Hand
arthralgia resolved, but knee arthralgia persisted during this period of time. The proportion of the
arthralgia-involved joints at 14 months differs from the reported by Schilte [7]. Fifty percent of the
patients from Schilte’s study in La Réunion had hand, knee and ankle arthralgia after 14 months.
However, Schilte studied 76 patients giving confidence to their study. In contrast, only four out of 52
of our patients could be interviewed by phone after 14 months of onset of symptoms. When we tried
to contact the patients, the phone number was incorrect, never answered or refused the interview. This
is a great bias; therefore, we included it for descriptive purposes and as evidence that Mexican patients
can continue with arthralgia at least 14 months after onset of symptoms.
We investigated the possibility of using combinations of clinical features for differentiating
between patients with CHIKF and patients with AUFI. The combination of arthralgia in wrist,
metacarpophalangeal joints and knee has a better specificity. Combination of arthralgia in the same
places plus adenopathy, arthritis and more than 30 arthralgia involved joints had a higher negative
predictive value.
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Furthermore, we sequenced the CHIKV infecting strains and associate the viruses with the
different clinical presentation. We reconfirmed that the Asian lineage was affecting the state of Chiapas
and was the responsible for the outbreak. We didn’t find the reported Brazilian ECSA CHIKV in Mexico.
Also, we didn’t find the single adaptive mutation in E1 (A226V) that confers a fitness advantage for
IOL strains in A. albopictus.
Here we found different circulating CHIKV strains. This can be explained because samples were
taken when the outbreak was still raging. Two of the sequences grouped with strains reported from
Yucatán. The collection date of the Yucatan samples is unknown, so we can only infer that viruses
were circulating between both states. It would be interesting to obtain the sequences of the viruses
from the following years to determine which of the clades persisted through time. In addition, the
whole genome sequencing could reveal a better picture of the virus phylogeny.
When the different CHIKV sequenced strains were associated with their spatial location in the
infection clusters there was no coincidence. Samples TA-689 and TA-755 shared the infection cluster
but were not in the same monophyletic group. It was not possible to sample every infection clusters
because most of the clusters were composed of IgM+ patients, so no viral RNA could be isolated
and sequenced.
We observed that patients infected with the divergent strain had more clinical features than
patients infected with the ancestral clade. This needs to be investigated thoroughly. This is the first
study to compare the clinical features of patients associated with CHIKV inter-lineage variation.
The patient infected with the strain that contained the non-synonymous mutation, A342V, had several
remarks. Even though both amino acids have a hydrophobic side chain, the effect in the viral protein
and its interaction with the host yet has to be determined.
We are aware that our study has limitations and should be addressed in the future. We only
obtained patients from one hospital that gives service to a specific type of population; therefore,
our sample was not truly representative of the general population. Also, our number of
chikungunya-negative patients was small to make strong associations and fully differentiate CHIKF
effectively. We were not able to establish a specific etiological agent for the Chikungunya-negative
patients. The number of patients infected with the ancestral clade is low, so findings are
simply observational.
5. Conclusions
We defined the complete clinical features of Chikungunya fever in 52 confirmed patients from
Southeastern Mexico. We obtained 10 new CHIKV E1 sequences and identified co-circulation of CHIKV
strains in the state of Chiapas. Different CHIKV strains were associated with different clinical features.
These findings can help to distinguish CHIKF from other febrile diseases and provide information
about genomic variants of this virus in Mexico.
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